Stock Analysis

Fibon Berhad Second Quarter 2025 Earnings: EPS: RM0.013 (vs RM0.011 in 2Q 2024)

KLSE:FIBON
Source: Shutterstock

Fibon Berhad (KLSE:FIBON) Second Quarter 2025 Results

Key Financial Results

  • Revenue: RM5.54m (up 26% from 2Q 2024).
  • Net income: RM1.32m (up 28% from 2Q 2024).
  • Profit margin: 24% (in line with 2Q 2024).
  • EPS: RM0.013 (up from RM0.011 in 2Q 2024).
earnings-and-revenue-history
KLSE:FIBON Earnings and Revenue History January 27th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fibon Berhad shares are up 2.4% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for Fibon Berhad (1 doesn't sit too well with us!) that you need to be mindful of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:FIBON

Fibon Berhad

An investment holding company, principally engages in the manufacture and trading of electrical insulators, electrical enclosures, meter boards, switchboards, and equipment parts.

Flawless balance sheet and good value.

Community Narratives

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Fair Value CHF 264.53|75.35300000000001% undervalued
kapirey
kapirey
Community Contributor
Top Pick for Multi-bagger
Fair Value US$44.06|47.367% undervalued
SuEric
SuEric
Community Contributor
Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth
Fair Value €148.18|9.232% undervalued
AurediusCapital
AurediusCapital
Community Contributor